Brainsway Ltd (BWAY)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $406.96M
Last updated: Nov 17, 2026 at 10:59 AM ET
Brainsway Ltd (BWAY) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Brainsway reported EPS of $0.10, below the $0.12 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
Analysts' consensus for the quarter ending Dec 31, 2026 is 266.7% above the $0.06 reported for the quarter ended Dec 31, 2025.
BWAY's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
BWAY Earnings Call
The latest BWAY earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 31 quarters below that had an estimate, BWAY beat 15, missed 7 and matched 9. Revenue for the quarter ended Sep 30, 2026 was $18.00M, up 33.2% from $13.51M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.10 | $0.12 | $0.07 - $0.12 | -16.67% | Miss | +400.0% | 3 | 1 up, 1 down | Nov 10, 2026 | $18.00M |
| Jun 30, 2026 | $0.14 | $0.10 | $0.05 - $0.10 | +40.00% | Beat | +366.7% | 3 | 1 up, 0 down | Aug 12, 2026 | $17.40M |
| Mar 31, 2026 | $0.06 | $0.05 | $0.03 - $0.06 | +20.00% | Beat | +500.0% | 3 | 3 up, 0 down | May 13, 2026 | $15.53M |
| Dec 31, 2025 | $0.06 | $0.05 | N/A | +39.91% | Beat | +59.5% | 3 | 0 up, 1 down | Mar 11, 2026 | $14.54M |
| Sep 30, 2025 | $0.02 | $0.02 | $0.02 - $0.03 | 0.00% | In line | +100.0% | 4 | 3 up, 0 down | Nov 11, 2025 | $13.51M |
| Jun 30, 2025 | $0.03 | $0.02 | $0.02 - $0.05 | +50.00% | Beat | +200.0% | 4 | 2 up, 1 down | Aug 13, 2025 | $12.63M |
| Mar 31, 2025 | $0.01 | $0.01 | $0.01 - $0.03 | 0.00% | In line | +49.3% | 3 | 1 up, 0 down | May 13, 2025 | $11.54M |
| Dec 31, 2024 | $0.04 | $0.04 | N/A | 0.00% | In line | +426.3% | 1 | 1 up, 0 down | Mar 11, 2025 | $11.41M |
| Sep 30, 2024 | $0.01 | $0.01 | $0.01 - $0.02 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Nov 12, 2024 | $10.50M |
| Jun 30, 2024 | $0.01 | -$0.01 | N/A | +200.00% | Beat | N/A | 1 | 0 up, 0 down | Aug 6, 2024 | $10.01M |
| Mar 31, 2024 | $0.01 | -$0.01 | -$0.01 - -$0.01 | +167.00% | Beat | N/A | 1 | 0 up, 0 down | May 8, 2024 | $9.10M |
| Dec 31, 2023 | $0.01 | -$0.01 | -$0.01 - -$0.01 | +176.00% | Beat | N/A | 2 | 0 up, 0 down | Mar 6, 2024 | $9.03M |
| Sep 30, 2023 | -$0.02 | -$0.02 | -$0.03 - -$0.02 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Nov 15, 2023 | $8.30M |
| Jun 30, 2023 | -$0.02 | -$0.02 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Aug 9, 2023 | $7.83M |
| Mar 31, 2023 | -$0.04 | -$0.05 | -$0.06 - -$0.05 | +20.00% | Beat | N/A | 2 | 0 up, 0 down | May 17, 2023 | $6.63M |
| Dec 31, 2022 | -$0.24 | -$0.26 | N/A | +7.69% | Beat | N/A | 2 | 0 up, 0 down | Mar 15, 2023 | $6.03M |
| Sep 30, 2022 | -$0.07 | -$0.06 | -$0.06 - -$0.06 | -16.67% | Miss | N/A | 2 | 0 up, 1 down | Nov 16, 2022 | $5.17M |
| Jun 30, 2022 | -$0.04 | -$0.03 | N/A | -33.33% | Miss | N/A | N/A | N/A | Aug 10, 2022 | $8.01M |
| Mar 31, 2022 | -$0.03 | -$0.04 | N/A | +25.00% | Beat | N/A | N/A | 0 up, 0 down | May 11, 2022 | $7.97M |
| Dec 31, 2021 | -$0.04 | -$0.05 | N/A | +20.00% | Beat | N/A | N/A | 0 up, 0 down | Mar 9, 2022 | $8.47M |
| Sep 30, 2021 | -$0.02 | -$0.02 | N/A | -33.33% | Miss | N/A | N/A | 0 up, 0 down | Nov 17, 2021 | $8.06M |
| Jun 30, 2021 | -$0.03 | -$0.03 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Aug 11, 2021 | $7.00M |
| Mar 31, 2021 | -$0.05 | -$0.06 | -$0.06 - -$0.06 | +16.67% | Beat | N/A | 1 | N/A | May 20, 2021 | $6.12M |
| Dec 31, 2020 | -$0.04 | -$0.04 | N/A | -14.29% | Miss | N/A | 1 | N/A | Mar 24, 2021 | $7.07M |
| Sep 30, 2020 | -$0.02 | -$0.02 | N/A | -33.33% | Miss | N/A | N/A | N/A | Nov 18, 2020 | $6.01M |
| Jun 30, 2020 | -$0.01 | -$0.06 | -$0.08 - -$0.06 | +83.33% | Beat | N/A | 2 | N/A | Aug 12, 2020 | $4.82M |
| Mar 31, 2020 | -$0.30 | -$0.30 | N/A | 0.00% | In line | N/A | 4 | N/A | Jun 24, 2020 | $4.16M |
| Dec 31, 2019 | -$0.05 | -$0.06 | -$0.06 - -$0.05 | +16.67% | Beat | N/A | 4 | N/A | Mar 23, 2020 | $6.29M |
| Sep 30, 2019 | -$0.12 | -$0.12 | -$0.12 - -$0.11 | 0.00% | In line | N/A | 4 | N/A | Nov 25, 2019 | $5.93M |
| Jun 30, 2019 | -$0.34 | -$0.26 | N/A | -30.77% | Miss | N/A | 3 | N/A | Aug 26, 2019 | $5.70M |
| Mar 31, 2019 | -$0.11 | -$0.14 | N/A | +21.43% | Beat | N/A | N/A | N/A | May 29, 2019 | $5.18M |
| Dec 31, 2018 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 27, 2019 | $4.77M |
| Sep 30, 2018 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2018 | $4.29M |
| Jun 30, 2018 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2018 | $3.73M |
| Mar 31, 2018 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2018 | $3.60M |
| Dec 31, 2017 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2017 | $3.60M |
| Sep 30, 2017 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2017 | $3.02M |
| Jun 30, 2017 | -$0.03 | N/A | N/A | N/A | N/A | -157.8% | N/A | N/A | Jun 30, 2017 | $2.38M |
| Mar 31, 2017 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2017 | $2.15M |
| Dec 31, 2016 | -$0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2016 | $2.88M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.12, up 85.6% from the year before. It was -$0.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.12 | +85.6% |
| Dec 31, 2024 | $0.07 | N/A |
| Dec 31, 2023 | -$0.07 | N/A |
| Dec 31, 2022 | -$0.38 | N/A |
| Dec 31, 2021 | -$0.14 | N/A |
| Dec 31, 2020 | -$0.37 | N/A |
| Dec 31, 2019 | -$0.62 | N/A |
| Dec 31, 2018 | -$0.12 | N/A |
| Dec 31, 2017 | -$0.48 | N/A |
| Dec 31, 2016 | -$0.17 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,000 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,973 | 6 | |
| 2026Q2 | Jun 30, 2026 | 3,898 | 6 | |
| 2026Q1 | Mar 31, 2026 | 4,185 | 6 | |
| 2025Q3 | Sep 30, 2025 | 3,303 | 7 | |
| 2025Q2 | Jun 30, 2025 | 2,860 | 7 | |
| 2025Q1 | Mar 31, 2025 | 2,981 | 6 | |
| 2024Q4 | Dec 31, 2024 | 4,010 | 8 | |
| 2024Q3 | Sep 30, 2024 | 3,089 | 7 |
2026Q3 Earnings Call
Opening remarks
Hadar Levy CEO Thank you, operator, and welcome, everyone. I'm pleased to report another strong quarter for BrainsWay, reflecting continued execution of our growth strategy, expanding adoption of Deep TMS, and further progress toward building a scalable and profitable business. Our ambition extends beyond selling medical devices. We are building a leading neurostimulation platform in mental health, supported by differentiated technology, expanding clinical indications, broader reimbursement, strategic partnerships, and an increasingly predictable recurring revenue model. During the third quarter, we shipped 130 Deep TMS systems, representing 44% year-over-year growth. Our global installed base now exceeds 2,000 systems, further expanding patient access to Deep TMS while creating additional opportunities for commercial leverage across our existing customers. Our financial results reflect this momentum, with revenue growing 34% year-over-year and remaining performance obligations reaching approximately $85 million, an increase of 31% compared with the prior year. We believe the continued growth in RPO demonstrates both strong market demand and the success of our recurring revenue model. Our multiyear agreements, high customer retention, and growing enterprise relationships provide greater visibility into future revenue while allowing us to deliver comprehensive, high-quality support to our customers. Importantly, we continue to demonstrate our ability to combine strong growth with operational discipline and profitability. Turning to clinical development, Deep TMS continued to build on one of the industry's most extensive bodies of peer-reviewed evidence, supported by multiple FDA clearances. During the quarter, we announced a peer-reviewed secondary analysis of our randomized clinical trial comparing SWIFT with standard once-daily Deep TMS. Among 89 patients with major depressive disorder, the number experiencing suicidal ideation declined from 20 at baseline to 6 after six weeks, representing a 70% relative reduction, with improvements observed across both protocols. We also announced encouraging results from a pilot study involving 12 patients with depression and early-stage Alzheimer's disease, reporting an 83% response rate and a 50% remission rate in depressive symptoms. While preliminary, the findings support further investigation. Deep TMS is not FDA-cleared for suicidal ideation or to treat Alzheimer's disease. Regarding PTSD among patients with coexisting depression, we continue to work through the regulatory review process. We believe a potential clearance would represent an important development, potentially allowing providers to address another significant unmet medical need using their existing Deep TMS system. Alongside this clinical advantage, we continue to make significant progress in reimbursement. Following the quarter, we announced that more than 70 million covered lives in the U.S. now have access to reimbursement policies covering our SWIFT accelerated protocol. We have also expanded OCD reimbursement coverage to approximately 180 million lives, while our adolescent depression clearance creates another opportunity to broaden access. We believe SWIFT represents one of our most significant long-term growth opportunities.
Frequently Asked Questions About BWAY
Did BWAY beat earnings estimates last quarter?
No. Brainsway reported EPS of $0.10 for the quarter ended Sep 30, 2026, below the $0.12 estimate by 16.67%.
What EPS do analysts expect from BWAY next quarter?
The consensus EPS estimate for Brainsway for the quarter ending Dec 31, 2026 is $0.22 from 3 analysts, with estimates from $0.21 to $0.23.
How often does BWAY beat earnings estimates?
Brainsway beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +16.66%.
BWAY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors